The SARS-CoV-2 virus vaccine being developed by the modern biotechnology company and the National Institute of Allergy and Infectious Diseases (NIAID) allowed volunteers who received a dose of it to generate antibodies to fight against disease.
This was indicated by a study that was published in The New England Journal of Medicine, which was rated by the director of the National Institute of Allergic and Infectious Diseases (NIAID), Anthony Fauci, as “very good news ». The vaccine that competes with others being developed to fight the coronavirus would not have caused serious side effects in citizens other than the flu, fatigue, headache, chills and pain at the site where it was applied.
Also read: Government announces protocol to reopen Managua International Airport to flights and demands on airlines
After these results, the vaccine called mRNA-1273 would enter the final phase of the trials that will involve 30,000 participants on July 27 and is expected to end in October 2022. The company assured that it would have results of the studies before of time.
“Neutralizing antibodies are the most important thing to protect against a viral infection,” Fauci said. “And the study data, even though the numbers are small, make it very clear that this vaccine is capable of inducing very good levels of neutralizing antibodies.” This trial was carried out with 45 volunteers aged between 18 and 55 years.
The company that is developing the vaccine, according to the Spanish media El País, was the first company to start human studies on the new coronavirus on March 16.
It may interest you: Minsa records 99 deaths from Covid-19 in Nicaragua since the start of the pandemic
“These phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response at all dose levels,” said Moderna chief medical officer Tal Zaks. The results of Phase 2 trials have not yet been published.
Seven months after the presence of the virus was reported, no cure has yet been found to slow its progress, however, researchers are working against the clock to develop vaccines and treatments to tackle the disease that has left more than 13 million infected people and more than 500 thousand dead.